Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL

Yücel Erbilgin, Sinem Firtina, PhD, Ozden Hatirnaz Ng, PhD, Tiraje Celkan, MD, Zeynep Karakas, MD, Seniye Sema Anak, MD, Nazan Sarper, MD, Emine Zengin, MD, Ahmet Eskazan, MD, Muge Sayitoglu, PhD, Ugur Ozbek, MD, PhD

Blood (2017) 130 (Supplement 1): 5110.

https://doi.org/10.1182/blood.V130.Suppl_1.5110.5110

Published: 2017

Journal Articles

Turkish National Severe Congenital Neutropenia Registry

Blood (2016) 128 (22): 4916.

https://doi.org/10.1182/blood.V128.22.4916.4916

Published: 2016

Journal Articles

Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia

Ahmet Emre Eskazan, MD, Mert Oztas, MD, Fatih Bektas, MD, Sevil Sadri, MD, Dilek Keskin, MD, Nurgul Ozgur Yurttas, MD, Selin Berk, MD, Isil Erdogan Ozunal, MD, Ayse Salihoglu, MD, M. Cem Ar, MD PhD, Seniz Ongoren, MD, Zafer Baslar, MD, Ugur Ozbek, MD PhD, Yildiz Aydin, MD, Teoman Soysal, MD

Blood (2016) 128 (22): 1905.

https://doi.org/10.1182/blood.V128.22.1905.1905

Published: 2016

Journal Articles

Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia

Eda Tanrikulu Simsek, MD, Ahmet Emre Eskazan, MD, Mahir Cengiz, MD, M. Cem Ar, MD PhD, Seda Ekizoglu, PhD, Ayse Salihoglu, MD, Emine Gulturk, MD, Tugrul Elverdi, MD, Seniz Ongoren Aydin, MD, Ahu Senem Demiroz, MD, Ayse Nur Buyru, MD, Zafer Baslar, MD, Ugur Ozbek, MD PhD, A. Burhan Ferhanoglu, MD, Yildiz Aydin, MD, Nukhet Tuzuner, MD Professor, Teoman Soysal, MD

Blood (2015) 126 (23): 2783.

https://doi.org/10.1182/blood.V126.23.2783.2783

Published: 2015

Journal Articles

New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition

M. Cem Ar, MD PhD, Emrah Yucesan, PhD, Firat Yalniz, MD, Ozden Hatirnaz Ng, PhD, Ayse Salihoglu, MD, Selin Berk, MD, Ahmet Emre Eskazan, MD, Seniz Ongoren, MD Associated Proffessor, Zafer Baslar, MD, Ugur Ozbek, MD PhD, Teoman Soysal, MD, Yildiz Aydin, MD, Muge Sayitoglu, PhD

Blood (2015) 126 (23): 77.

https://doi.org/10.1182/blood.V126.23.77.77

Published: 2015

Journal Articles

Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update

Guray Saydam, MD Prof, Ibrahim Celalettin Haznedaroglu, MD, Leylagul Kaynar, MD, Akif S. Yavuz, MD Prof, Ridvan Ali, Prof MD, Birol Guvenc, MD Prof, Olga M. Akay, MD, Zafer Baslar, Professor Doctor, Ugur Ozbek, MD PhD, Mehmet Sonmez, MD, Demet Aydin, MD, Mustafa Pehlivan, MD Assoc Prof, Bulent Undar, MD Prof, Simten Dagdas, MD Assoc Prof, Orhan M. Ayyildiz, MD Prof, Diyar Z. Akkaynak, MD, Ilkiz M. Dag, MD, Osman Ilhan, MD

Blood (2014) 124 (21): 5532.

https://doi.org/10.1182/blood.V124.21.5532.5532

Published: 2014

Journal Articles

Genetic and Epigenetic Profile Of Early Relapsed Childhood ALL

Yucel Erbilgin, Ozden Hatirnaz Ng, PhD, Sinem Firtina, Tiraje Celkan, Sema Anak, MD, Zeynep Karakas, MD, Aykan Ozguven, MD, Nazan Sarper, MD, Emine Zengin, MD, Emine Turkkan, MD, Didem Yalcin Atay, MD, Yuk Yin Ng, PhD, Omer Dogru, MD, Muge Sayitoglu, PhD, Ugur Ozbek

Blood (2013) 122 (21): 1380.

https://doi.org/10.1182/blood.V122.21.1380.1380

Published: 2013

Journal Articles

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

Blood (2013) 122 (21): 3824.

https://doi.org/10.1182/blood.V122.21.3824.3824

Published: 2013

Journal Articles

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Guray Saydam, MD, Prof, Ibrahim C. Haznedaroglu, MD, Prof, Leylagul Kaynar, MD, Prof, Akif S. Yavuz, MD, Prof, Ridvan Ali, MD, Prof, Birol Guvenc, MD, Prof, Olga M. Akay, MD, Zafer Baslar, Professor Doctor, Ugur Ozbek, MD, Prof, Mehmet Sonmez, M.D., Demet Aydin, MD, Mustafa Pehlivan, MD, Assoc Prof, Bulent Undar, MD, Prof, Simten Dagdas, MD, Assoc Prof, Orhan M. Ayyildiz, MD, Prof, Diyar Z. Akkaynak, MD, Ilkiz M. Dag, MD, Osman Ilhan, MD, Prof

Blood (2013) 122 (21): 2742.

https://doi.org/10.1182/blood.V122.21.2742.2742

Published: 2013

Journal Articles

Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance

Yucel Erbilgin, Ahmet Emre Eskazan, Ozden Hatirnaz Ng, PhD, Ayse Salihoglu, Tugrul Elverdi, MD, Sinem Firtina, Suzin Catal Tatonyan, Seniz Ongoren Aydin, Muhlis Cem Ar, Zafer Baslar, Muge Sayitoglu, PhD, A. Burhan Ferhanoglu, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2013) 122 (21): 384.

https://doi.org/10.1182/blood.V122.21.384.384

Published: 2013

Journal Articles

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Blood (2012) 120 (21): 1399.

https://doi.org/10.1182/blood.V120.21.1399.1399

Published: 2012

Journal Articles

Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia

Ahmet Emre Eskazan, Suzin Catal Tatonyan, Ayse Salihoglu, Emine Gulturk, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, A. Burhan Ferhanoglu, Nukhet Tuzuner, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2011) 118 (21): 1692.

https://doi.org/10.1182/blood.V118.21.1692.1692

Published: 2011

Journal Articles

Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience

Suzan Alp, Ayse Salihoglu, Ahmet Emre Eskazan, Emine Gulturk, M. Cem Ar, Seniz Ongoren Aydin, Zafer Baslar, Ayse Nur Buyru, Ugur Ozbek, A. Burhan Ferhanoglu, Yildiz Aydin, Teoman Soysal

Blood (2011) 118 (21): 4429.

https://doi.org/10.1182/blood.V118.21.4429.4429

Published: 2011

Journal Articles

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia

Mustafa Sevinc, Ahmet Emre Eskazan, Aydin Karabulut, Msc, Suzin Catal Tatonyan, Emine Gulturk, Ayse Salihoglu, Seniz Ongoren Aydin, M. Cem Ar, Zafer Baslar, A. Burhan Ferhanoglu, Nukhet Tuzuner, Yildiz Aydin, Ugur Ozbek, Teoman Soysal

Blood (2011) 118 (21): 4603.

https://doi.org/10.1182/blood.V118.21.4603.4603

Published: 2011

Journal Articles

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Martin C. Müller, MD, Umang Munjal, PhD, Philipp Erben, MD, Thomas Lion, MD, PhD, Gerlinde Mitterbauer-Hohendanner, MD, Hakim El Housni, MD, Nancy Boeckx, Renata Zadro, MD, PhD, Jiri Mayer, MD, PhD, Peter Rohon, MD, Jana Rulcova, PhD, Lykke Grubach, Kadri Raudsepp, MD, Veli Kairisto, MD, PhD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, MD, Sandrine Hayette, MD, Jean Gabert, MD, Jean-Michel Cayuela, MD, PhD, Christian Thiede, Lars Galonska, MD, Heike Pfeifer, MD, Carsten Hirt, MD, Philippe Schafhausen, MD, Nils von Neuhoff, PhD, Martin Roskos, MD, Christiane Pott, MD, Thoralf Lange, MD, Georg Hess, MD, Susanne Schnittger, PhD, Annika Dufour, MD, Steffen Koschmieder, MD, Frank Stegelmann, MD, Katerina Zoi, MD, PhD, Kostas Stamatopoulos, Hajnalka Andrikovics, MD, PhD, Tali Tohami, MD, PhD, Giovanni Martinelli, MD, Barbara Izzo, PhD, Enrico Gottardi, MD, Mindaugas Stoskus, Dag Andre Nymoen, MD, Tomasz Sacha, MD, Joana Diamond, MD, PhD, Rodica Talmaci, PhD, Andrey Misyurin, MD, Michael V. Dubina, MD, Tadej Pajic, MD, PhD, Josep F. Nomdedeu, MD, Dolors Colomer, MD, PhD, Gisela Barbany-Bustinza, MD, Hans Ehrencrona, MD, Elisabeth Oppliger Leibundgut, PhD, Jeroen Janssen, MD, Vincent H. J. van der elden, MD, Peter J.M. Valk, MD, PhD, Ugur Ozbek, MD, PhD, Lihui Wang, Gareth Gerrard, PhD, Helen E White, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Rüdiger Hehlmann, MD, Giuseppe Saglio, MD, PhD, Andreas Hochhaus, MD, Nicholas C. P. Cross, PhD

Blood (2010) 116 (21): 893.

https://doi.org/10.1182/blood.V116.21.893.893

Published: 2010

Journal Articles

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Blood (2010) 116 (21): 894.

https://doi.org/10.1182/blood.V116.21.894.894

Published: 2010

Journal Articles

Development of Standardized Approaches to Reporting of Minimal Residual Disease Data Using a Reporting Software Package Designed within the European LeukemiaNet (ELN).

Charlotte G Nyvold, M.Sci., PhD, Mette Oestergaard, M.Sci., PhD, Morten T Andersen, M.Sci., Jelena V Jovanovic, Veli Kairisto, M.D., PhD, Jan K Larsen, MM.Sci., Yvonne G Morgan, Dr., Ugur Ozbek, M.D., PhD, Prof., Niels Pallisgaard, M.Sci., Heike Pfeifer, M.D., David Grimwade, PhD, FRCPath, Peter Hokland, M.D., D., Med., Sci.

Blood (2009) 114 (22): 1619.

https://doi.org/10.1182/blood.V114.22.1619.1619

Published: 2009

Journal Articles

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Blood (2009) 113 (19): 4497–4504.

https://doi.org/10.1182/blood-2008-12-191254

Published: 2009

Includes: Supplemental data

Journal Articles

Upregulation of FZ5 Results in Abberant Expression of Beta-Catenin and LEF/TCF Complex in Acute Myeloid Leukemia.

Fatmahan Atalar, PhD, Ozden Hatirnaz, MSc, Yucel Erbilgin, BSc, Ugur Ozbek, MD, PhD, Muge Sayitoglu, PhD

Blood (2006) 108 (11): 4316.

https://doi.org/10.1182/blood.V108.11.4316.4316

Published: 2006

Journal Articles

Different Activation of WNT Signaling Pathway in B-Cell and T-Cell Acute Leukemias.

Muge Sayitoglu, PhD, Ozden Hatirnaz, MSc, Yucel Erbilgin, Fatmahan Atalar, PhD, Ugur Ozbek, MD PhD

Blood (2006) 108 (11): 4317.

https://doi.org/10.1182/blood.V108.11.4317.4317

Published: 2006

NARROW

IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL

Turkish National Severe Congenital Neutropenia Registry

Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia

Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia

New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition

Nilotinib Results in Improved Rates of Molecular Response in Turkish Newly Diagnosed CML-CP Patients: A 24-Month Update

Genetic and Epigenetic Profile Of Early Relapsed Childhood ALL

Sensitivity, Reproducibility and Clinical Utility Of Next-Generation Sequencing (NGS) for BCR-ABL1 Kinase Domain Mutation Screening: Results From The CML Work Package Of The Iron-II (Interlaboratory RObustness Of Next-Generation Sequencing) International Study

Use Of Nilotinib As a First Line Treatment In Adult Patients With Philadelphia Chromosome-Positive and Chronic Phase Myeloid Leukemia

Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance

The Interlaboratory Robustness of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses of Hematological Malignancies Performed by an International Network Involving 26 Laboratories

Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia

Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia

Stability of Conversion Factors for BCR-ABL Monitoring -– Implications for the Frequency of Validation Rounds

Harmonized Testing for BCR-ABL Kinase Domain Mutations In CML: Results of a Survey and First Control Round within 28 National Reference Laboratories In Europe

Development of Standardized Approaches to Reporting of Minimal Residual Disease Data Using a Reporting Software Package Designed within the European LeukemiaNet (ELN).

Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

Upregulation of FZ5 Results in Abberant Expression of Beta-Catenin and LEF/TCF Complex in Acute Myeloid Leukemia.

Different Activation of WNT Signaling Pathway in B-Cell and T-Cell Acute Leukemias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only